Quan Ni

Dr. Ni has been a part of the Inspire team since 2008. Dr. Ni led therapy development and clinical research during feasibility and pivotal clinical trials, which led to FDA approval of Inspire therapy as a new treatment option for OSA in 2014. Prior to Inspire, Dr. Ni held leadership positions with Boston Scientific and Guidant Corporation. Dr. Ni holds more than 100 granted patents and has authored numerous peer reviewed publications. He has a B.S. from Shanghai Jiaotong University, China, an M.S. from University of California, San Diego and Ph.D. in Bioengineering from the University of Utah.